TY - JOUR T1 - Modelling outbreak response strategies for preventing spread of emergent <em>Neisseria gonorrhoeae</em> strains in men who have sex with men in Australia JF - medRxiv DO - 10.1101/2021.04.30.21256375 SP - 2021.04.30.21256375 AU - Qibin Duan AU - Chris Carmody AU - Basil Donovan AU - Rebecca J Guy AU - Ben B Hui AU - John M Kaldor AU - Monica M Lahra AU - Matthew G Law AU - David A Lewis AU - Michael Maley AU - Skye McGregor AU - Anna McNulty AU - Christine Selvey AU - David J Templeton AU - David M Whiley AU - David G Regan AU - James G Wood Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/03/2021.04.30.21256375.abstract N2 - The ability to treat gonorrhoea with current first-line drugs is threatened by the global spread of extensively drug resistant (XDR) Neisseria gonorrhoeae (NG) strains. In Australia, urban transmission is high among men who have sex with men (MSM) and emergence of an imported XDR NG strain in this population could result in an epidemic that would be difficult and costly to control. An individual-based, anatomical site-specific mathematical model of NG transmission among Australian MSM was developed and used to evaluate the potential for elimination of an emergent XDR NG strain under a range of case-based and population-based test-and-treat strategies. When applied upon detection of the imported strain, these strategies enhanced the probability of elimination and reduced the outbreak size compared with current practice. The most effective strategies combined testing targeted at regular and casual partners with increased rates of population testing. However, even with the most effective strategies, outbreaks could persist for up to 2 years post-detection. Our simulations suggest that local elimination of emergent NG XDR strains can be achieved with high probability using combined case-based and population-based test-and-treat strategies. These strategies may be an effective means of preserving current treatments in the event of wider XDR NG emergence.Author Summary In most high-income settings, gonorrhoea transmission is endemic among men who have sex with men (MSM). While gonorrhoea remains readily treatable, there are major concerns about further resistance due to recent reports of treatment failure with first-line therapy and limited remaining treatment options. Here we investigated the potential for trace and treat response strategies to eliminate such strains before their prevalence reaches a level requiring a shift to new first line therapies. Rather than directly consider resistance, we explore the mitigating effect of various test and trace measures on outbreaks of a generic imported strain which remains treatable. This is done within a realistic mathematical model of spread in an MSM community that captures cases, anatomical sites of infection and contacts at an individual level, calibrated to Australian epidemiology. The results indicate that strategies such as partner tracing and treatment in combination with elevated asymptomatic community testing are highly effective in mitigating outbreaks but can take up to 2 years to achieve elimination. As there are currently no clear alternatives of proven efficacy and safety to replace ceftriaxone in first-line therapy, these promising results suggest potential for use of these outbreak response strategies to enable continuation of current treatment recommendations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Australian National Health and Medical Research Commission (NHMRC) under grant number APP1145642.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article its supplementary material. ER -